Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Relationship between myeloma cell genomic alternations and tumor immune microenvironment in bone-related extramedullary disease of newly diagnosed multiple myeloma

View Full Paper
Ask AI
Bookmark
Share

Authors

YXYang Xu

Discussion

Loading...

Member takes

Overview

Analysis reveals TP53 abnormalities correlate with immune microenvironment changes, indicating potential therapeutic targets in multiple myeloma.

Key Points

  • TP53 abnormalities increase regulatory T cell populations and impair effector T cell function, fostering immune suppression.
  • Single-cell RNA sequencing and CyTOF analysis demonstrate significant alterations in immune cell profiles associated with TP53 mutations.
  • Analysis of bone-related extramedullary disease highlights the importance of genetic alterations on immune responses in newly diagnosed multiple myeloma.
  • These findings suggest that targeting CD38 may prove more effective for treating TP53-aberrant cases in multiple myeloma.

Cite This Study

Yang Xu (2025) studied this question.

synapsesocial.com/papers/69362f484fa91c937236d6d4https://doi.org/10.1182/blood-2025-5722
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Multi-omics profiling reveals an immunosuppressive microenvironment and PRL-3 as a therapeutic target in myeloma extramedullary disease2025
  2. 2Spatially resolved transcriptomics reveals immunosuppressive niches and clonal diversity in extramedullary disease in multiple myeloma refractory to immunotherapy2025
  3. 3Genomic and transcriptomic signatures of extramedullary multiple myeloma reveal possible drivers of therapeutic resistance2025
  4. 4Dissecting the multiple myeloma survival niche to improve novel treatment strategies2025
  5. 5Single-cell transcriptomics reveals proliferative, immune-evasive, and bone marrow–independent transcriptional programs in extramedullary multiple myeloma.2025